Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dermoscopy helps diagnose frontal fibrosing alopecia by identifying specific scalp features.

This review discusses the non-follicular skin manifestations of frontal fibrosing alopecia and how they affect diagnosis and treatment, but reports no new clinical results.

This article describes a case of frontal fibrosing alopecia in a patient with chronic lichenoid lupus erythematosus and notes the lack of similar documented cases in existing literature.

This study revealed distinct cellular and transcriptomic differences among various subtypes of cutaneous T-cell lymphoma, particularly highlighting characteristics unique to folliculotropic mycosis fungoides.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This review covers the clinical presentation and challenges in treating frontal fibrosing alopecia in postmenopausal women and concludes that more research is needed to understand its etiology and develop effective treatments.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

A rare skin condition causes red and dark patches on the face and limbs.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This study reports that familial frontal fibrosing alopecia was diagnosed earlier in premenopausal women compared to postmenopausal women, though long-term outcomes remain uncertain without a definitive treatment.

This study reported that prompt diagnosis and treatment with 5-alpha-reductase inhibitors and topical immunomodulators are key to mitigating the effects of frontal fibrosing alopecia and preventing permanent hair loss.

This case report describes a 50-year-old woman with frontal fibrosing alopecia who showed no improvement despite multiple treatments, including intralesional triamcinolone and topical glucocorticoids.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

This study found that loss of the folliculin protein delays transferrin receptor recycling, leading to iron deficiency and suggesting a role in the mechanisms of Birt-Hogg-Dubé syndrome.

This review discusses fibrosing frontal alopecia, including its causes, mechanisms, and treatments, and emphasizes the need for further research to improve understanding and treatments; it reports no new clinical results.

This study suggests that the interaction between folliculin and plakophilin-4 (p0071) may play a role in folliculin's tumor suppressor function by regulating RhoA signaling, impacting cell migration and junction formation.

Confocal Laser Scanning Microscopy (CLSM) is a useful tool for studying how drugs interact with skin and diagnosing skin disorders, despite some limitations.

In this study, the CYP 21A2 gene p.V281L mutation was associated with an increased susceptibility to familial frontal fibrosing alopecia, suggesting an antigen-driven mechanism linked to certain human leukocyte antigen haplotypes.

This study reports a case of frontal fibrosing alopecia associated with hepatitis C treatment involving interferon and ribavirin.

This report presents the first Australian case of familial frontal fibrosing alopecia involving a mother and daughter and seeks to differentiate clinical features between familial and sporadic cases.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

This case series describes Erythromelanosis follicularis faciei et colli in five Indian patients, suggesting it may be more common than currently reported.

This study found that the locked cheek lift technique effectively corrects cheek gravitational migration and reduces the lid cheek distance with minimal complications, maintaining results for over a year.

This study reported that frontal fibrosing alopecia predominantly affects postmenopausal women and identified potential risk factors like frequent β-blocker use and sunscreen application, indicating the need for further research.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

In this study, 2′‐Fucosyllactose (2′‐FL) administration significantly reduced hair loss and increased hair length and thickness in a testosterone-induced androgenic alopecia mouse model, suggesting potential as a therapeutic agent for AGA.

PCFCL may have unrecognized subtypes and needs more research.

This study concluded that removing alopecia and mucous membrane components from the CLASI-A score limits the ability to capture crucial clinical information about cutaneous lupus erythematosus activity, recommending their retention.

This correspondence discusses proposed updates to the diagnostic criteria for frontal fibrosing alopecia, emphasizing the importance of differentiating it from other types of alopecia.